GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
NCT06948435 on ClinicalTrials.gov

Status
Active not recruitingResults none
Why it is watched
non-weight indication: cardiovascular
Who it enrolls
age 18 Years to no upper limit; no BMI minimum stated; conditions: Hypertension; Overweight or Obesity
Interventions
Orforglipron; Placebo
Conditions
Hypertension; Overweight or Obesity
Phase and size
Phase 3 · 487 participants
Dates
Start 2025-04-30
Primary completion 2027-09
Sponsor
Eli Lilly and Company (Industry)
Last checked
Sep 13, 2026
01Endpoints

What the trial will measure

  • Change from Baseline in office Systolic Blood Pressure (SBP)Baseline to Week 36
02Eligibility

Who can take part

Inclusion Criteria: * refer to the GZPL master protocol for screening eligibility. Exclusion Criteria: * refer to the GZPL master protocol for screening eligibility.
03Change log

Registry changes

No changes recorded since the trial was added.